| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GHRHR |
| Uniprot No | Q02643 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-132aa |
| 氨基酸序列 | HMHPECDFITQLREDESACLQAAEEMPNTTLGCPATWDGLLCWPTAGSGE WVTLPCPDFFSHFSSESGAVKRDCTITGWSEPFPPYPVACPVPLELLAEE ESYFSTVKII |
| 预测分子量 | 38 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GHRHR(生长激素释放激素受体)重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**: "Cloning and functional characterization of the human growth hormone-releasing hormone receptor"
**作者**: Gaylinn BD, et al.
**摘要**: 该研究首次成功克隆了人类GHRHR基因，并在哺乳动物细胞中表达重组蛋白。通过体外结合实验证实，重组受体能够特异性结合生长激素释放激素(GHRH)，并激活cAMP信号通路，为后续研究GHRHR的生理功能及药物开发奠定基础。
---
2. **文献名称**: "Expression and purification of recombinant GHRHR extracellular domain for antibody production"
**作者**: Zhang Y, et al.
**摘要**: 研究团队通过原核表达系统(大肠杆菌)高效表达并纯化了GHRHR的胞外结构域重组蛋白。该蛋白被用作抗原制备多克隆抗体，验证了抗体在Western blot和免疫组化中对天然GHRHR的特异性识别能力，为受体定位研究提供工具。
---
3. **文献名称**: "Structural insights into GHRHR activation by GHRH through cryo-EM analysis"
**作者**: Liang YL, et al.
**摘要**: 利用冷冻电镜技术解析了GHRHR与GHRH肽及Gs蛋白复合物的三维结构，揭示了配体结合后受体构象变化及信号转导机制。重组GHRHR蛋白的稳定表达和纯化是结构解析的关键步骤，该研究为靶向GHRHR的药物设计提供结构基础。
---
注：以上文献为示例性质，实际引用需根据具体研究领域补充近年研究(如2020年后关于GHRHR重组蛋白在肿瘤或代谢疾病模型中的应用)。
**Background of GHRHR Recombinant Protein**
GHRHR (Growth Hormone-Releasing Hormone Receptor) is a G protein-coupled receptor (GPCR) primarily expressed in the anterior pituitary gland. It plays a critical role in regulating growth hormone (GH) synthesis and secretion by binding to its endogenous ligand, growth hormone-releasing hormone (GHRH). Activation of GHRHR triggers intracellular signaling cascades, predominantly via the cAMP-PKA pathway, ultimately stimulating pituitary somatotroph cells to release GH. This hormonal axis is essential for normal growth, metabolism, and tissue repair.
Recombinant GHRHR protein is engineered using molecular cloning techniques, often expressed in mammalian or insect cell systems to ensure proper post-translational modifications and structural integrity. The recombinant form retains the receptor's functional domains, including its extracellular ligand-binding region and transmembrane helices, enabling its use in vitro and in vivo studies. Researchers employ it to investigate GHRHR signaling mechanisms, ligand-receptor interactions, and dysregulation in diseases such as growth hormone deficiency, acromegaly, or pituitary tumors.
Beyond basic research, GHRHR recombinant protein has therapeutic potential. Mutations or dysfunction in GHRHR are linked to growth disorders, making it a target for drug development. Recombinant analogs or antagonists of GHRHR are explored for treating GH-related pathologies. Additionally, the protein serves as a tool for diagnostic assay development and screening of compounds that modulate GH secretion.
Studying GHRHR also contributes to understanding GPCR biology, a major drug target class. Its recombinant form facilitates structural studies (e.g., crystallography) to elucidate activation mechanisms, aiding the design of biased ligands with improved efficacy and safety profiles. Overall, GHRHR recombinant protein bridges molecular insights into endocrine regulation and translational applications in biomedicine.
×
